A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer
- Borstlap, W.A.
- Tanis, P.J.
- Koedam, T.W.
- Marijnen, C.A.
- Cunningham, C.
- Dekker, E.
- Leerdam, M.E. van
- Meijer, G.
- Grieken, N. van
- Nagtegaal, I.D.
- Punt, C.J.A.
- Dijkgraaf, M.G.
- Wilt, J.H.W. de
- Beets, G.
- Graaf, E.J. de
- Geloven, A.A. van
- Gerhards, M.F.
- Westreenen, H.L. van
- Ven, A.W.H. van de
- Duijvendijk, P. van
- Hingh, I.H. de
- Leijtens, J.W.A.
- Sietses, C.
- Spillenaar-Bilgen, E.J.
- Vuylsteke, R.J.
- Hoff, C.
- Burger, J.W.
- Grevenstein, W.M. van
- Pronk, A.
- Bosker, R.J.
- Prins, H.
- Smits, A.B.
- Bruin, S. de
- Zimmerman, D.D.
- Stassen, L.P.
- Dunker, M.S.
- Westerterp, M.
- Coene, P.P.
- Stoot, J.
- Bemelman, W.A.
- Tuynman, J.B.
DOIAbstract
Contains fulltext : 172310.pdf (publisher's version ) (Open Access)BACKGROUND: Rectal cancer surgery is accompanied with high morbidity and poor long term functional outcome. Screening programs have shown a shift towards more early staged cancers. Patients with early rectal cancer can potentially benefit significantly from rectal preserving therapy. For the earliest stage cancers, local excision is sufficient when the risk of lymph node disease and subsequent recurrence is below 5 %. However, the majority of early cancers are associated with an intermediate risk of lymph node involvement (5-20 %) suggesting that local excision alone is not sufficient, while completion radical surgery, which is currently standard of care, c...
Add to ORKG